TW201249827A - Novel inhibitors of hepatitis C virus - Google Patents

Novel inhibitors of hepatitis C virus Download PDF

Info

Publication number
TW201249827A
TW201249827A TW100140412A TW100140412A TW201249827A TW 201249827 A TW201249827 A TW 201249827A TW 100140412 A TW100140412 A TW 100140412A TW 100140412 A TW100140412 A TW 100140412A TW 201249827 A TW201249827 A TW 201249827A
Authority
TW
Taiwan
Prior art keywords
alkyl
group
mmol
methyl
cycloalkyl
Prior art date
Application number
TW100140412A
Other languages
English (en)
Chinese (zh)
Inventor
Robert Murray Mckinnell
Daniel D Long
Orden Lori Jean Van
Lan Jiang
Mandy Loo
Daisuke Roland Saito
Sheila Zipfel
Eric L Stangeland
Kassandra Lepack
Gavin Ogawa
Xiaojun Huang
Weijiang Zhang
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of TW201249827A publication Critical patent/TW201249827A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW100140412A 2010-11-04 2011-11-04 Novel inhibitors of hepatitis C virus TW201249827A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41026710P 2010-11-04 2010-11-04
US201161444046P 2011-02-17 2011-02-17
US201161492267P 2011-06-01 2011-06-01

Publications (1)

Publication Number Publication Date
TW201249827A true TW201249827A (en) 2012-12-16

Family

ID=44993923

Family Applications (1)

Application Number Title Priority Date Filing Date
TW100140412A TW201249827A (en) 2010-11-04 2011-11-04 Novel inhibitors of hepatitis C virus

Country Status (9)

Country Link
US (2) US8921372B2 (enExample)
EP (1) EP2635571B1 (enExample)
JP (1) JP5891235B2 (enExample)
CN (1) CN103189371B (enExample)
AR (1) AR083757A1 (enExample)
CA (1) CA2814534A1 (enExample)
ES (1) ES2548286T3 (enExample)
TW (1) TW201249827A (enExample)
WO (1) WO2012061552A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI577672B (zh) * 2011-11-03 2017-04-11 施萬生物製藥研發Ip有限責任公司 C型肝炎病毒抑制劑

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ581823A (en) * 2007-06-12 2012-09-28 Technolines Llc High speed and high power laser scribing system with a laser, mirror and controller
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
RS52854B (sr) 2009-06-11 2013-12-31 Abbvie Bahamas Limited Inhibitori hepatitis c virusa
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2012061552A1 (en) * 2010-11-04 2012-05-10 Theravance, Inc. Novel inhibitors of hepatitis c virus
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
SI2723732T1 (sl) 2011-06-22 2017-05-31 Purdue Pharma Lp One Stamford Forum Antagonisti trpv1, vključno z dihidroksi substituentom, in njihova uporaba
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PT2850075T (pt) 2012-04-25 2017-05-02 Theravance Biopharma R&D Ip Llc Compostos de piperazina-piperidina como inibidores do vírus da hepatite c
CA2869908C (en) * 2012-04-25 2018-02-20 Theravance Biopharma R&D Ip, Llc Hepatitis c virus inhibitors
WO2013165796A1 (en) * 2012-05-03 2013-11-07 Theravance, Inc. Crystalline form of a pyridyl-piperazinyl hepatitis c virus inhibitor
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hcvの治療に使用するためのビフェニル誘導体を含む組み合わせ
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN105175401A (zh) * 2015-10-16 2015-12-23 北京康立生医药技术开发有限公司 一种依匹哌唑的制备方法
CN112409336B (zh) * 2017-11-27 2021-09-14 常州寅盛药业有限公司 适于工业化生产的达卡他韦起始原料的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0421908D0 (en) * 2004-10-01 2004-11-03 Angeletti P Ist Richerche Bio New uses
PT1940786E (pt) * 2005-09-16 2010-10-04 Arrow Therapeutics Ltd Derivados de bifenilo e sua utilização no tratamento de hepatite c
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101558059B (zh) * 2006-08-11 2014-12-03 百时美施贵宝公司 丙型肝炎病毒抑制剂
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7910722B2 (en) * 2007-07-05 2011-03-22 Florida State University Research Foundation RNAi therapeutic for treatment of hepatitis C infection
SI2250163T1 (sl) 2008-02-12 2012-08-31 Bristol Myers Squibb Co Hepatitis c virus inhibitorji
JP2012510525A (ja) 2008-12-03 2012-05-10 プレシディオ ファーマシューティカルズ インコーポレイテッド Hcvns5aの阻害剤
WO2010094977A1 (en) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
EP2398474A4 (en) 2009-02-23 2012-12-05 Presidio Pharmaceuticals Inc HCV NS5A SHEMMER
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011031934A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011153396A1 (en) 2010-06-04 2011-12-08 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
WO2012061552A1 (en) * 2010-11-04 2012-05-10 Theravance, Inc. Novel inhibitors of hepatitis c virus
SG11201401891RA (en) 2011-11-03 2014-05-29 Theravance Inc Rod -like hepatitis c virus inhibitors containing the fragement {2- [4- (bi phenyl - 4 - yl) - 1h - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl} amine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI577672B (zh) * 2011-11-03 2017-04-11 施萬生物製藥研發Ip有限責任公司 C型肝炎病毒抑制劑

Also Published As

Publication number Publication date
US20150071878A1 (en) 2015-03-12
AR083757A1 (es) 2013-03-20
US8921372B2 (en) 2014-12-30
EP2635571A1 (en) 2013-09-11
CN103189371B (zh) 2015-04-01
CN103189371A (zh) 2013-07-03
JP5891235B2 (ja) 2016-03-22
WO2012061552A1 (en) 2012-05-10
CA2814534A1 (en) 2012-05-10
US20120114600A1 (en) 2012-05-10
US9260414B2 (en) 2016-02-16
ES2548286T3 (es) 2015-10-15
JP2013544812A (ja) 2013-12-19
EP2635571B1 (en) 2015-08-12

Similar Documents

Publication Publication Date Title
TW201249827A (en) Novel inhibitors of hepatitis C virus
EP2773634B1 (en) Rod-like hepatitis c virus inhibitors containing the fragement {2-[4-(biphenyl-4-yl)-1h-imidazo-2-yl]pyrrolidine-1-carbonlymethyl}amine
CN102741241B (zh) 苯并咪唑-咪唑衍生物
TW201033197A (en) Inhibitors of HCV NS5A
EP2850072B1 (en) Hepatitis c virus inhibitors
JP6069491B2 (ja) C型肝炎ウイルス阻害剤としてのピペラジン−ピペリジン化合物
NZ623846B2 (en) Rod-like hepatitis c virus inhibitors containing the fragment {2-[4-(bi phenyl-4-yl) -1h-imidazo-2-yl] pyrrolidine-1-carbonlymethyl} amine